The Ocular Melanoma drugs in development market research report provides comprehensive information on the therapeutics under development for Ocular Melanoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Ocular Melanoma. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Ocular Melanoma and features dormant and discontinued products.
GlobalData tracks 94 drugs in development for Ocular Melanoma by 75 companies/universities/institutes. The top development phase for Ocular Melanoma is phase ii with 47 drugs in that stage. The Ocular Melanoma pipeline has 85 drugs in development by companies and nine by universities/ institutes. Some of the companies in the Ocular Melanoma pipeline products market are: Bristol-Myers Squibb, Pfizer and Novartis.
The key targets in the Ocular Melanoma pipeline products market include Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1), Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4), and Cells Expressing Melanoma Antigen Preferentially Expressed In Tumors (Cancer/Testis Antigen 130 or Opa Interacting Protein 4 or OIP4 or Preferentially Expressed Antigen Of Melanoma or PRAME).
The key mechanisms of action in the Ocular Melanoma pipeline product include Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) Antagonist with six drugs in Phase II. The Ocular Melanoma pipeline products include 17 routes of administration with the top ROA being Intravenous and 16 key molecule types in the Ocular Melanoma pipeline products market including Small Molecule, and Monoclonal Antibody.
Ocular Melanoma overview
Ocular melanoma is an extremely rare form of cancer that affects the eye with an incidence of 5 per million adults. Although rare, it is the most common primary cancer of the eye in adults. Primary means that the cancer began at that site (in this case the eye) and did not spread there from another part of the body
For a complete picture of Ocular Melanoma’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
